Federico Salamone, Fabio Galvano, Giovanni Li Volti – 26 August 2010

Katrina J. Allen, Nadine A. Bertalli, Nicholas J. Osborne, Clare C. Constantine, Martin B. Delatycki, Amy E. Nisselle, Amanda J. Nicoll, Dorota M. Gertig, Christine E. McLaren, Graham G. Giles, John L. Hopper, Gregory J. Anderson, John K. Olynyk, Lawrie W. Powell, Lyle C.

Stephen A. Harrison, Lorenzo Rossaro, Ke‐Qin Hu, Keyur Patel, Hans Tillmann, Sandeep Dhaliwal, Dawn M. Torres, Kenneth Koury, Venkata S. Goteti, Stephanie Noviello, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Mark S. Sulkowski – 26 August 2010 – Elevated low‐density lipoprotein (LDL) levels and statin use have been associated with higher sustained virological response (SVR) rates in patients receiving chronic hepatitis C therapy. However, these relationships have not been well characterized in randomized controlled trials.

Darmendra Ramcharran, Abdus S. Wahed, Hari S. Conjeevaram, Rhobert W. Evans, Tianyi Wang, Steven H. Belle, Leland J. Yee, for the Virahep‐C Study Group – 26 August 2010 – Approximately one half of patients who undergo antiviral therapy for chronic hepatitis C virus (HCV) genotype 1 infection do not respond to treatment. African Americans (AAs) are less responsive to treatment than Caucasian Americans (CAs), but the reasons for this disparity are largely unknown. Recent studies suggest that serum lipids may be associated with treatment response.

Rohit Kohli, Michelle Kirby, Stavra A. Xanthakos, Samir Softic, Ariel E. Feldstein, Vijay Saxena, Peter H. Tang, Lili Miles, Michael V. Miles, William F. Balistreri, Stephen C. Woods, Randy J. Seeley – 26 August 2010 – Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans.

Xu‐Feng Zhang, Xinping Tan, Gang Zeng, Amalea Misse, Sucha Singh, Youngsoo Kim, James E. Klaunig, Satdarshan P. S. Monga – 26 August 2010 – Activation of β‐catenin, the central effector of the canonical Wnt pathway and a recognized oncogene, has been implicated in hepatocellular carcinoma. We examined N‐nitrosodiethylamine (DEN)‐induced tumorigenesis in hepatic β‐catenin conditional knockout mice (β‐cat KO). Male β‐cat KO and age‐ and sex‐matched littermate controls were given a single intraperitoneal DEN injection and followed for 6‐12 months for hepatic tumors.

Yavuz Beyazit, Murat Kekilli, Tugrul Purnak, Mevlut Kurt – 26 August 2010

Kshaunish Das – 26 August 2010

Andrew J. Muir, Mitchell L. Shiffman, Atif Zaman, Boris Yoffe, Andrew de la Torre, Steven Flamm, Stuart C. Gordon, Paul Marotta, John M. Vierling, Juan Carlos Lopez‐Talavera, Kelly Byrnes‐Blake, David Fontana, Jeremy Freeman, Todd Gray, Diana Hausman, Naomi N. Hunder, Eric Lawitz – 26 August 2010 – Interferon lambda 1 (IFN‐λ1) is a type III IFN that produces intracellular responses similar to those of IFN‐α but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile.

Zong‐Gen Peng, Bo Fan, Na‐Na Du, Yu‐Ping Wang, Li‐Mei Gao, Ying‐Hong Li, Yu‐Huan Li, Fei Liu, Xue‐Fu You, Yan‐Xing Han, Zhi‐Yun Zhao, Shan Cen, Jian‐Rui Li, Dan‐Qing Song, Jian‐Dong Jiang – 26 August 2010 – Host heat shock cognate 70 (Hsc70) protein is packaged into hepatitis C viral (HCV) particles as a structural component of the virus in the assembly process. It helps HCV RNA release into the cytoplasm in the next infection cycle. The goal of this study is to investigate whether chemically down‐regulating host Hsc70 expression could be a novel strategy to interrupt HCV replication.